GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL is supported by a differentiated clinical dataset for Galleri, including PATHFINDER 2’s 60% positive-predictive value, 39% sensitivity, and NHS-Galleri’s 14% reduction in Stage IV cancers, alongside CSO accuracy above 90% and specificity of 99.6%. Those results, combined with a large and underpenetrated market that could exceed 100 million annual U.S. tests, support a long runway for adoption if FDA approval and Medicare coverage continue to advance. Financially, 1Q revenue grew 28% and Galleri sales rose 37% on 50% volume growth, while gross margin improved to 48% and cash ended at $823 million, reinforcing the company’s ability to fund commercialization.

GRAIL is burdened by persistent net losses, a high cash burn profile, and a commercialization model that requires heavy ongoing sales, marketing, and clinical-study spending just to build demand for Galleri, while total operating expenses are expected to remain materially above revenue for the next five years. Its outlook is further pressured by regulatory and reimbursement uncertainty, since the FDA has never approved an MCED test, broader Medicare coverage is not yet in place, and a negative approval outcome would confine Galleri to structurally narrow cash-pay and employer channels. Competitive and operational risks also weigh on fundamentals, including limited self-pay willingness at a $949 price point, weak conversion, a likely ASP decline, rising costs from a resuming ~7% Illumina royalty in 2027, and reliance on sole suppliers and third parties.